December 20, 2018 10:30 AM EST

G1 touts PhII cancer data, but shares tank on placebo results; Merck bags another approved indication for Keytruda

John Carroll

Editor & Founder

→ G1 Therapeutics $GTHX tried their level best to tout the results of their Phase II study of trilaciclib in combination with topotecan for small …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

G1 touts PhII cancer data, but shares tank on placebo results; Merck bags another approved indication for Keytruda

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

‘Just the beginning’: Nobel Prizes show the AI era has arrived in biotech

Zealand Pharma hit with second CRL for glucagon receptor agonist

AI biotech insitro partners with Lilly on metabolic disease drugs

Crinetics’ $500M offering; Boehringer inks deal with macrocycles biotech

Exclusive Q&A: FDA's principal deputy commissioner on taking over for Califf, adcomms, accelerated approvals and more

CMS looks to $2 out-of-pocket cap for some commonly used generic drugs

G1 touts PhII can­cer da­ta, but shares tank on place­bo re­sults; Mer­ck bags an­oth­er ap­proved in­di­ca­tion for Keytru­da

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

G1 touts PhII cancer data, but shares tank on placebo results; Merck bags another approved indication for Keytruda